Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity

[1]  J. Murray,et al.  Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  P Kronqvist,et al.  Cysteine proteinase inhibitor cystatin A in breast cancer. , 1998, Cancer research.

[3]  Pamela J. Fink,et al.  Maximal Proliferation of Cytotoxic T Lymphocytes Requires Reverse Signaling through Fas Ligand , 1998, The Journal of experimental medicine.

[4]  M. D. Val,et al.  Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation. , 1997, Journal of immunology.

[5]  L. Hicke.  Ubiquitin‐dependent internalization and down‐regulation of plasma membrane proteins , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  C. Pickart.  Targeting of substrates to the 26S proteasome , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  A. Goldberg,et al.  Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[9]  J. Bluestone,et al.  Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.

[10]  J. Yewdell,et al.  The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing? , 1997, Journal of immunology.

[11]  R. Siliciano,et al.  Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization , 1997, The Journal of experimental medicine.

[12]  T. Waldmann,et al.  Effects of the tyrosine‐kinase inhibitor geldanamycin on ligand‐induced HER‐2/NEU activation, receptor expression and proliferation of HER‐2‐positive malignant cell lines , 1997, International journal of cancer.

[13]  E. Halapi,et al.  Mechanisms of escape from CD8+ T‐cell clones specific for the HER‐2/NEU proto‐oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression , 1997, International journal of cancer.

[14]  J. Bryant,et al.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.

[15]  L. Neckers,et al.  Polyubiquitination and Proteasomal Degradation of the p185c-erbB-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin* , 1996, The Journal of Biological Chemistry.

[16]  G. Huang,et al.  Human Cancer Cells Exhibit Protein Kinase C-dependent c-erbB-2 Transmodulation That Correlates with Phosphatase Sensitivity and Kinase Activity* , 1996, The Journal of Biological Chemistry.

[17]  H. Pircher,et al.  On the role of antigen in maintaining cytotoxic T-cell memory. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  N. Shastri,et al.  Generation of naturally processed peptide/MHC class I complexes is independent of the stability of endogenously synthesized precursors. , 1996, Journal of immunology.

[19]  J. Yewdell,et al.  Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , 1996, Journal of immunology.

[20]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[21]  J. Berzofsky,et al.  Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL , 1996, The Journal of experimental medicine.

[22]  T. Mak,et al.  Duration of TCR stimulation determines costimulatory requirement of T cells. , 1996, Immunity.

[23]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[24]  J. Sprent,et al.  Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro , 1996, The Journal of experimental medicine.

[25]  C. Hahn,et al.  The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen , 1996, The Journal of experimental medicine.

[26]  A. Lanzavecchia,et al.  Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy , 1996, The Journal of experimental medicine.

[27]  L. Neckers,et al.  p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. , 1996, The Journal of biological chemistry.

[28]  A. Goldberg,et al.  Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. , 1995, Journal of immunology.

[29]  H. Schreiber,et al.  Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of Experimental Medicine.

[31]  N. Ward,et al.  Irreversible Inactivation of Protein Kinase C by a Peptide-Substrate Analog (*) , 1995, The Journal of Biological Chemistry.

[32]  J. Yewdell,et al.  Presentation of endogenous and exogenous antigens is not affected by inactivation of E1 ubiquitin-activating enzyme in temperature-sensitive cell lines. , 1995, Journal of Immunology.

[33]  D. Margulies,et al.  Determinant selection of major histocompatibility complex class I- restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues , 1994, The Journal of experimental medicine.

[34]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[35]  A. Houghton.  Cancer antigens: immune recognition of self and altered self , 1994, The Journal of experimental medicine.

[36]  J. Wharton,et al.  Sequence motifs of human her-2 protooncogene important for Peptide binding to hla-A2. , 1994, International journal of oncology.

[37]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[38]  M. Cheever,et al.  In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. , 1994, Cancer research.

[39]  J. Wharton,et al.  Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. , 1993, Cellular immunology.

[40]  A. Goldberg,et al.  A role for the ubiquitin-dependent proteolytic pathway in MHC class l-restricted antigen presentation , 1993, Nature.

[41]  M. Grooteclaes,et al.  Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. , 1993, Oncogene.

[42]  Y. Yarden,et al.  Cell‐type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER‐2 suggests complex ligand‐receptor relationships. , 1993, The EMBO journal.

[43]  O. Larsson,et al.  Carcinomas and Melanomas CTL Against Autologous and Allogeneic Peptide Epitopes That Can Elicit Specific Derived neu-Identification of New HER 2 / , 1999 .

[44]  D. Hanahan,et al.  Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. , 1996, The Journal of clinical investigation.

[45]  Gerold Schuler,et al.  Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.